<DOC>
	<DOC>NCT02107391</DOC>
	<brief_summary>The purpose of this study is to determine whether DCVAC/PCa added onto hormone therapy can improve PSA progression times for patients with Metastatic Prostate Cancer.</brief_summary>
	<brief_title>Phase II Study of DCVAC/PCa Added to Hormone Therapy for Men With Metastatic Prostate Cancer</brief_title>
	<detailed_description>Use of vaccine to improve Prostate Specific Antigen (PSA) levels.</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Hormones</mesh_term>
	<mesh_term>Leuprolide</mesh_term>
	<mesh_term>Goserelin</mesh_term>
	<criteria>Male 18 years and older Histologically confirmed prostate adenocarcinoma Presence of bone or soft tissue metastasis (by CT or PET or MRI and/or scintigraphy) Androgen deprivation therapy using Luteinizinghormonereleasing hormone ( LHRH) analogues commenced at least one month and at most three months prior randomization or orchiectomy performed at least one month and at most three months prior randomization Serum testosterone level at screening (≤ 1.7 nmol/l, resp. ≤ 50 ng/dL) Eastern Cooperative Oncology Group (ECOG) 02 Confirmed brain and/or leptomeningeal metastases Prior or ongoing chemotherapy for prostate cancer Peripheral neuropathy of Common Toxicity Criteria (CTC) grade 2 or greater Other uncontrolled intercurrent illness Treatment with immunotherapy against prostate cancer Clinically significant cardiovascular disease Active autoimmune disease requiring treatment</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2015</verification_date>
	<keyword>Immunotherapy</keyword>
	<keyword>Prostate Cancer</keyword>
	<keyword>Biological</keyword>
	<keyword>Vaccine</keyword>
	<keyword>Androgen Deprivation Therapy</keyword>
</DOC>